Page 53 - Read Online

Girotti et al. J Cancer Metastasis Treat 2020;6:52 I http://dx.doi.org/10.20517/2394-4722.2020.107 Page 15 of 15

54. Bhowmick R, Girotti AW. Pro-survival and pro-growth effects of stress-induced nitric oxide in a prostate cancer photodynamic therapy
model. Cancer Lett 2014;343:115-22.
55. Fahey JM, Girotti AW. Accelerated migration and invasion of prostate cancer cells after a photodynamic therapy-like challenge: role of
nitric oxide. Nitric Oxide 2015;49:47-55.
56. Fahey JM, Emmer JV, Korytowski W, Hogg N, Girotti AW. Antagonistic effects of endogenous nitric oxide in a glioblastoma
photodynamic therapy model. Photochem Photobiol 2016;92:842-53.
57. Lancaster JR. The use of diaminofluorescein for nitric oxide detection; conceptual and methodological distinction between NO and
nitrosation. Free Radic Biol Med 2010;49:1145.
58. Fahey JM, Girotti AW. Nitric oxide-mediated resistance to photodynamic therapy in a human breast tumor xenograft model: improved
outcome with NOS2 inhibitors. Nitric Oxide 2017;62:52-61.
59. Fahey JM, Korytowski W, Girotti AW. Upstream signaling events leading to elevated production of pro-survival nitric oxide in
photodynamically-challenged glioblastoma cells. Free Radic Biol Med 2019;137:37-45.
60. Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Cenin Cancer Biol 2000;10:415-33.
61. Korbelik M. Role of cell stress signaling networks in cancer cell death and antitumor immune response following proteotoxic injury
inflicted by photodynamic therapy. Lasers Surg Med 2018;50:491-8.
62. Huang B, Yang XD, Zhow MM, Ozato K, Chen LF. Brd4 coactivates transcriptional activation of NF-κB via specific binding of
acetylated RelA. Mol Cell Biol 2009;29:1375-87.
63. Fahey JM, Stancill JS, Smith BC, Girotti AW. Nitric oxide antagonism to glioblastoma photodynamic therapy and mitigation thereof by
BET bromodomain inhibitor JQ1. J Biol Chem 2018;293:5345-59.
64. Shikima N, Lyon J, La Thangue NB. The p300/CBP family: integrating signals with transcription factors and chromatin. Trends Cell Biol
1997;7:230-6.
65. Goodman RH, Smolik S. CBP/p300 in cell growth, transformation, and development. Genes Dev 2000;14:1553-77.
66. Zin ZH, Fang DY. The roles of SIRT1 in cancer. Genes Cancer 2013;4:97-104.
67. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase/Akt pathway in human cancer. Nat Rev Canc 2002;2:489-501.
68. Niziolek M, Korytowski W, Girotti AW. Chain-breaking antioxidant and cytoprotective action of nitric oxide on photodynamically
stressed tumor cells. Photochem Photobiol 2003;78:262-70.
69. Zareba M, Niziolek M, Korytowski W, Girotti AW. Merocyanine 540-sensitized photokilling of leukemia cells: role of post-irradiation
chain peroxidation of plasma membrane lipids as revealed by nitric oxide protection. Biochim Biophys Acta 2005;1722:51-9.
70. Rubbo H, Radi R, Trujillo M, et al. Nitric oxide regulation of superoxide and peroxynitrite-dependent lipid peroxidation. J Biol Chem
1994;269:26066-75.
71. Korbelik M, Cecic I, Sluiter W. PDT-induced nitrosative stress. SPIE International Symposium on Biomedical Optics, 2002.
72. Park HS, Huh SH, Kim MS, Lee SH, Choi EJ. Nitric oxide negatively regulates c-Jun N-terminal kinase/stress-activated protein by means
of S-nitrosylation. Proc Natl Acad Sci USA 2000;97:14382-7.
73. Li CQ, Wogan GN. Nitric oxide as a modulator of apoptosis. Cancer let 2005;226:1-15.
74. Azad N, Vallyathan V, Tantishaiyakul V, Stehlik C, Leonard SS, Yon Rojanasakul. S-nitrosylation of Bcl-2 inhibits its ubiquitin-
proteasomal degradation a novel antiapoptotic mechanism that suppresses apoptosis. J BIOL CHEM 2006;281:34124-34.
75. Guan WP, Sha JB, Chen XJ, Xing YL, Yan JQ, Wang ZQ. Nitrosylation of mitogen activated protein kinase phosphatase-1 suppresses
radiation-induced apoptosis. Cancer Lett 2012;314:137-46.
76. Stomberski CT, Hess DT, Stamler JS. Protein S-nitrosylation: determinants of specificity and enzymatic regulation of S-nitrosothiol-based
signaling. Antiox Redox Signal 2017;10:1331-51.
77. Matsumoto H, Hayashi S, Hatashita M, et al. Induction of radioresistance by a nitric oxide-mediated bystander effect. Radiat Res
2001;155:387-96.
78. Yakovlev VA. Role of nitric oxide in the radiation-induced bystander effect. Redox Biol 2015;6:396-400.
79. Bazak J, Fahey JM, Wawak K, Korytowski W, Girotti AW. Enhanced aggressiveness of bystander cells in an anti-tumor photodynamic
therapy model: role of nitric oxide produced by targeted cells. Free Radic Biol Med 2017;102:111-21.
80. Bazak J, Korytowski W, Girotti AW. Bystander effects of nitric oxide in cellular models of anti-tumor photodynamic therapy. Cancers
(Basel) 2019;11:1674.
81. Hansel TT, Kharitonov SA, Donnelly LE, et al. A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide
in healthy volunteers and asthmatics. FASEB J 2003;17:1298-317.
82. Singh D, Richards D, Knowles RG, et al. Selective inducible initric oxide synthase inhibition has no effect on allergen challenge in
asthma. Am J Respir Crit Care Med 2007;176:988-93.
83. Shu S, Polyak K. BET bromodomain proteins as cancer therapeutic targets. Cold Spring Harb Symp Quant Biol 2016;81:123-9.
84. Filippakopoulos P, Qi J, Picaud S, et al. Selective inhibition of BET bromodomains. Nature 2010;468:1067-173.
85. Filippakopoulos P, Knapp S. Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov 2014;13:337-56.
86. Lam FC, Morton SW, Wyckoff J, et al. Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas
using targeted nanoparticles. Nat Commun 2018;9:1991.